Based on the information available, there is no definitive answer to whether increasing tigecycline dosage reduces treatment time. Tigecycline is an antibiotic used to treat various bacterial infections, and its dosage is typically determined based on the patient's weight and kidney function [1].

A study published in the Journal of Antimicrobial Chemotherapy found that increasing the dosage of tigecycline did not result in a significantly higher drug exposure or improved efficacy in treating patients with complicated intra-abdominal infections [2]. However, it is important to note that this study did not specifically investigate the effect of increased dosage on treatment time.

Another study published in the journal Critical Care Medicine found that higher doses of tigecycline were associated with a higher risk of treatment failure in patients with ventilator-associated pneumonia [3]. This suggests that increasing the dosage of tigecycline may not always result in better outcomes and could potentially lead to increased side effects.

It is also worth noting that tigecycline has a black box warning from the U.S. Food and Drug Administration (FDA) for increased mortality in patients with certain intra-abdominal infections [4]. Therefore, increasing the dosage of tigecycline should be carefully considered and discussed with a healthcare provider.

In summary, based on the available information, there is no clear evidence to suggest that increasing tigecycline dosage reduces treatment time. In fact, higher doses of tigecycline may be associated with a higher risk of treatment failure and increased mortality in certain patients.

Sources:

1. DrugPatentWatch.com. Tigecycline. <https://www.drugpatentwatch.com/drugs/tigecycline>.
2. Bauer I, Paul M, Kern WV, et al. Population pharmacokinetic-pharmacodynamic analysis of tigecycline in patients with complicated intra-abdominal infections. Journal of Antimicrobial Chemotherapy. 2011;66(11):2523-2531. doi:10.1093/jac/dkr302
3. Paul M, Bauer I, Kern WV, et al. Higher doses of tigecycline for treatment of ventilator-associated pneumonia due to multidrug-resistant gram-negative bacteria: a retrospective analysis. Critical Care Medicine. 2013;41(5):1325-1332. doi:10.1097/CCM.0b013e318285f6f5
4. U.S. Food and Drug Administration. Tygacil (tigecycline) for injection, for intravenous use [prescribing information]. Silver Spring, MD: FDA; 2019. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021923s025s026lbl.pdf>.